iRhythm Holdings, Inc.
iRhythm Holdings, Inc. develops and commercializes ambulatory cardiac monitoring systems built around a wearable patch sensor and cloud-based ECG analytics. Its products are used to record heart rhythm data over extended periods so clinicians can detect and diagnose arrhythmias more efficiently, with sales concentrated in the United States and supported by smaller commercial footprints in Europe and Japan.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenuePatch-based biosensors and related software used to capture and analyze ECG data over multiple days.
Products
Reported · share of revenue- Commercial Payors52.5 %
- Centers for Medicare and Medicaid24.0 %
- Healthcare Institutions16.8 %
- Non Contracted Third Party Payors6.7 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
iRhythm sells primarily to healthcare providers and healthcare systems that order ambulatory cardiac monitoring for patients with suspected arrhythmias. Its services are reimbursed mainly through contracted third-party payors and Medicare, with additional demand from hospitals and private physician practices that purchase directly.
Cardiologists, electrophysiologists, neurologists, and other physicians order Zio monitoring to diagnose arrhythmias.
Large provider networks adopt iRhythm for standardized, value-based cardiac monitoring workflows.
Commercial payors and CMS reimburse the monitoring service, shaping utilization and pricing.
Some institutions purchase the service directly when they want outsourced ambulatory monitoring.
Strategy
iRhythm’s strategy centers on expanding adoption of its patch-based monitoring platform among physicians, health systems, and risk-bearing entities. It also relies on reimbursement access, clinical evidence, and workflow integration to make its service a preferred alternative to traditional Holter and event monitors.
The business depends on recurring ordering by clinicians and health systems for monitoring volume.
Revenue is highly dependent on Medicare and commercial payor coverage and payment levels.
Europe and Japan provide additional growth avenues beyond the core U.S. market.
Product performance, ease of use, and physician acceptance drive competitive wins.
Geography
The United States is the core market and accounts for the vast majority of revenue. Outside the U.S., iRhythm has smaller operating footprints in the UK, parts of continental Europe, and Japan through direct teams and distributor relationships.
Risks
iRhythm is exposed to reimbursement, regulatory, manufacturing, and supply-chain risks because its service depends on payor coverage, regulated medical-device components, and accurate clinical reporting. It also faces competition from large medical-device companies and smaller monitoring providers, while international expansion adds regulatory and operational complexity.
- Reimbursement changes or denial of coverageImpact: HighLikelihood: Medium
Most revenue depends on Medicare and contracted third-party payors, so payment policy directly affects demand and realized revenue.
Exposure: U.S. payor and CMS reimbursement
- Medical-device regulatory and quality complianceImpact: HighLikelihood: Medium
The biosensor and software are regulated products, and failures can trigger recalls, holds, or enforcement actions.
Exposure - Supply-chain and manufacturing disruptionImpact: HighLikelihood: Medium
The company relies on third-party vendors and some critical components have limited alternative sources.
Exposure: Components and printed circuit board assembly
- Competitive pressure in remote cardiac monitoringImpact: MediumLikelihood: Medium
Large incumbents and regional providers compete on price, physician acceptance, and reimbursement access.
Exposure - International expansion execution riskImpact: MediumLikelihood: Low
Operating outside the U.S. introduces regulatory, political, and commercial complexity.
Exposure
Accounting
Judgemental itemsThe company estimates collectible amounts based on payor history, contracts, and reimbursement developments, which can materially change reported revenue.
Impact: Affects net revenue and receivables
Management notes lower revenue in the third quarter and during holiday periods as patients and physicians delay monitoring.
Impact: Quarter-to-quarter comparability
Collections depend on commercial payors, government programs, and patients, creating estimation risk.
Impact: Affects operating results and receivables
Device components and finished goods must be valued carefully if demand, obsolescence, or supply conditions change.
Impact: Affects cost of revenue and assets
Facility leases and acquisition-related obligations require judgment and can affect earnings and balance sheet values.
Impact: Affects operating expenses and liabilities
Similar listed companies
Publicly listed companies with a comparable business focus.
Biotricity Inc.
BTCY · Surgical & Medical Instruments & Apparatus
HeartSciences Inc.
HSCSW · Finance Services
HeartBeam, Inc.
BEAT · Surgical & Medical Instruments & Apparatus
Rhythm Pharmaceuticals, Inc
RYTM · Pharmaceutical Preparations
Rhythm Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for rare genetic disorders of obesity and related metabolic diseases.
Medtronic plc
MDT · Electromedical & Electrotherapeutic Apparatus
Medtronic plc designs, manufactures, and sells medical technologies used to diagnose, treat, and manage chronic and acute conditions across the body.
iHeartMedia, Inc.
IHRT · Radio Broadcasting Stations
Last updated: 24/09/2026